Succinyl-(Glu9,Ala11·15)-Endothelin-1 (8-21)

Research use only, not for human use.

IRL-1620 is a potent and selective endothelin receptor type B (ETB) agonist with a Ki of 16 pM.

IRL-1620 is an effective and selective agonist of endothelin receptor type B (ETB) (Ki: 16 pM).

IRL-1620 is the most potent and specific ligand for the ETB receptor (KiETA/ KiETB=120,000) as judged by the Ki values for ETA (19 μM) and ETB (16 PM) receptors. IRL-1620 is 60 times more selective for the ETB receptor than ET-3 (KiETA/ KiETB=1,900).

IRL-1620 (1-100 nM) induces contractions of the guinea pig trachea. The effective concentration that produces 30 % of 60 mM KCI-induced contraction is estimated to be 28 nM for IRL 1620. IRL-1620 (1-100 nM) increases cytosolic Ca2+ in the vascular endothelium ([Ca]E) with little effect on resting muscle tone, and relaxes the norepinephrine-stimulated tone with an increase in [Ca]E, in rat aorta,. IRL-1620 improves both acquisition (learning) and retention (memory) on the water maze task and enhances angiogenic and neurogenic remodeling. Rats treated with IRL-1620 significantly reduces the cognitive impairment induced by Aβ. IRL-1620 treatment enhances the number of blood vessels labeled with VEGF compared to vehicle treatment.

———

Others

Other Targets

Endothelin receptor B;Endothelin receptor A

———

———

142569-99-1

1820.974

C86H117N17O27

>98% (HPLC)

———

———

——

(-20℃)

With Ice Pack

≥ 2 years